

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
11 May 2023 (11.05.2023)



(10) International Publication Number
WO 2023/079493 A1

(51) International Patent Classification:

A61P 35/00 (2006.01) C07K 16/28 (2006.01)
A61P 35/02 (2006.01)

(21) International Application Number:

PCT/IB2022/060614

(22) International Filing Date:

03 November 2022 (03.11.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

21206329.1	03 November 2021 (03.11.2021)	EP
21213774.9	10 December 2021 (10.12.2021)	EP
22187329.2	27 July 2022 (27.07.2022)	EP
63/369,602	27 July 2022 (27.07.2022)	US

(71) Applicants: **AFFIMED GMBH** [DE/DE]; Technologiepark, Im Neuenheimer Feld 582, 69120 Heidelberg (DE).
AFFIVANT SCIENCES GMBH [CH/CH]; Viaduktstrasse 8, 4051 Basel (CH).

(72) Inventors: **KOCH, Joachim**; c/o AFFIMED GMBH, Technologiepark, Im Neuenheimer Feld 582, 69120 Heidelberg (DE). **PAHL, Jens**; c/o AFFIMED GMBH, Technologiepark, Im Neuenheimer Feld 582, 69120 Heidelberg (DE). **ROSS, Thorsten**; c/o AFFIMED GMBH, Technologiepark, Im Neuenheimer Feld 582, 69120 Heidelberg (DE). **SIEGLER, Jana-Julia**; c/o AFFIMED GMBH, Technologiepark, Im Neuenheimer Feld 582, 69120 Heidelberg (DE). **DULAT, Holger**; c/o AFFIMED GMBH, Technologiepark, Im Neuenheimer Feld 582, 69120 Heidelberg (DE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))
— with sequence listing part of description (Rule 5.2(a))
— in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(54) Title: BISPECIFIC CD16A BINDERS

(57) Abstract: The present invention relates to a bispecific antibody construct comprising (a) a first binding domain (A), which is capable of specifically binding to a first target (A') that is CD16A on the surface of an immune effector cell, wherein the first binding domain comprises: (i) a VL region comprising CDR-L1 as depicted in SEQ ID NO: 4, a CDR-L2 as depicted in SEQ ID NO: 5, and a CDR-L3 as depicted in SEQ ID NO: 6; and (ii) a VH region as depicted in SEQ ID NO: 7; and (b) a second binding domain (B), which is capable of specifically binding to a second target (B') that is an antigen on the surface of a target cell, wherein the second target (B') is FOLR1. The present invention also relates to related nucleic acid molecules, vectors, host cells, methods of producing the antibody constructs, pharmaceutical compositions, medical uses, and kits.



WO 2023/079493 A1